Article ; Online: Efectos adversos de lopinavir/ritonavir en enfermedad grave por coronavirus (COVID-19).
2020 Volume 80, Issue 5, Page(s) 439–441
Abstract: During the SARSCoV-2 pandemic many drugs have been used as potential treatments in order to improve the clinical outcome and reduce the mortality. But since it is a currently unknown disease, the evidence about efficacy and safety is built as the drugs ... ...
Title translation | Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19. |
---|---|
Abstract | During the SARSCoV-2 pandemic many drugs have been used as potential treatments in order to improve the clinical outcome and reduce the mortality. But since it is a currently unknown disease, the evidence about efficacy and safety is built as the drugs are prescribed. In this context, intensive pharmacovigilance allows early detection of adverse events, and thereby infer the safety profile of the indication. We conducted an observational, retrospective, single-center study involving adult patients with severe SARS-CoV-2 infection. All adverse events detected in 23 patients in the Intensive Care Unit between March 15 and June 15, 2020 were registered. We describe type and severity of the adverse events and if treatment suspension was needed. The results show a high rate of adverse events (10/23, 43%) in treatment with lopinavir/ritonavir. In most cases early treatment suspension was required. Even though the limitations of our study derived from the small sample size, these results could help in building evidence about the safety of using lopinavir/ritonavir for severe SARS-CoV-2 infection. |
MeSH term(s) | Adult ; Aged ; Argentina/epidemiology ; Betacoronavirus ; Coronavirus Infections/drug therapy ; Coronavirus Infections/epidemiology ; Critical Illness ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Cytochrome P-450 CYP3A Inhibitors/therapeutic use ; Female ; Humans ; Lopinavir/adverse effects ; Lopinavir/therapeutic use ; Male ; Pandemics ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/epidemiology ; Retrospective Studies ; Ritonavir/adverse effects ; Ritonavir/therapeutic use ; Treatment Outcome |
Chemical Substances | Cytochrome P-450 CYP3A Inhibitors ; Lopinavir (2494G1JF75) ; Ritonavir (O3J8G9O825) |
Keywords | covid19 |
Language | Spanish |
Publishing date | 2020-10-13 |
Publishing country | Argentina |
Document type | Journal Article |
ZDB-ID | 411586-7 |
ISSN | 1669-9106 ; 0025-7680 ; 0325-951X |
ISSN (online) | 1669-9106 |
ISSN | 0025-7680 ; 0325-951X |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.B 163: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.